2023
Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States
Swartwood N, Testa C, Cohen T, Marks S, Hill A, Beeler Asay G, Cochran J, Cranston K, Randall L, Tibbs A, Horsburgh C, Salomon J, Menzies N. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Medicine 2023, 21: 331. PMID: 37649031, PMCID: PMC10469407, DOI: 10.1186/s12916-023-02785-y.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotic ProphylaxisCost of IllnessFemaleHumansLatent TuberculosisParturitionPregnancyTuberculosisUnited StatesConceptsLatent tuberculosis infectionTB outcomesDistrict of ColumbiaTreatment of LTBIIncremental cost-effectiveness ratioTB incidence rateTuberculosis disease burdenQuality-adjusted life yearsCost-effectiveness ratioPublic health agenciesTB casesTB preventionTB incidenceTuberculosis infectionTB epidemiologyDisease burdenIncidence rateService utilizationAdditional interventionsIncidence projectionsLife yearsDemographic dataSocietal perspectiveHealth agenciesPrevention approaches
2017
Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers
Kunkel A, Lewnard JA, Pitzer VE, Cohen T. Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00026-17. PMID: 28533237, PMCID: PMC5527623, DOI: 10.1128/aac.00026-17.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsAntibiotic ProphylaxisCholeraDisease OutbreaksDrug Resistance, BacterialHaitiHumansModels, TheoreticalRiskUnited NationsVibrio choleraeConceptsDrug-resistant infectionsAntimicrobial chemoprophylaxisDrug-sensitive infectionsDrug resistance generationCholera importationChemoprophylaxisDrug resistanceImportation eventsInfectionAntibiotic resistanceAntimicrobial resistance risksRiskRelative benefitsResistance generationCholeraPotential resistance risksPotential benefitsResistance riskProphylaxisPrevalence
2015
How could preventive therapy affect the prevalence of drug resistance? Causes and consequences
Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosophical Transactions Of The Royal Society B Biological Sciences 2015, 370: 20140306. PMID: 25918446, PMCID: PMC4424438, DOI: 10.1098/rstb.2014.0306.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotic ProphylaxisCommunicable Disease ControlComputer SimulationDrug Resistance, MicrobialHumansInfectionsModels, TheoreticalPrevalenceConceptsPreventative therapyDrug resistanceDrug-sensitive pathogensProphylactic antimicrobial therapyLong-term prevalenceSmall pilot studyActive diseaseOverall prevalenceAntimicrobial therapyPrevalencePilot studyTherapyPopulation-level changesPotential population-level effectsDirect effectLevel of coveragePopulation-level effectsHIVTuberculosisMalariaDiseaseCare